SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

AMG 517

Item No. 26191

CAS Registry No.:	659730-32-2
Formal Name:	N-[4-[[6-[4-(trifluoromethyl) phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]-acetamide
MF:	$C_{20}H_{13}F_3N_4O_2S$
FW:	430.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 247, 272 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AMG 517 is supplied as a crystalline solid. A stock solution may be made by dissolving the AMG 517 in the solvent of choice. AMG 517 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of AMG 517 in these solvents is approximately 3.3, 14.3, and 112.5 mg/ml, respectively.

Description

AMG 517 is an antagonist of transient receptor potential vanilloid 1 (TRPV1; IC_{50} = 0.9 nM).[1] It inhibits mechanical and thermal allodynia in a rat model of burn injury when administered intrathecally at a dose of 165 µg.[2] AMG 517 (150 and 300 µg/kg) also reverses increases in the level of calcitonin gene-related peptide (CGRP) and increases expression of GFAP and GAP-43 in the dorsal horn of the spinal cord, as well as enhances axonal regeneration in a rat model of sciatic nerve transection injury.[3]

References

1. Blum, C.A., Caldwell, T., Zheng, X., *et al*. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists. *J. Med. Chem*. **53(8)**, 3330-3348 (2010).
2. Green, D.P., Ruparel, S., Gao, X., *et al*. Central activation of TRPV1 and TRPA1 by novel endogenous agonists contributes to mechanical allodynia and thermal hyperalgesia after burn injury. *Mol. Pain* **12**, (2016).
3. Bai, J., Liu, F., Wu, L.-F., *et al*. Attenuation of TRPV1 by AMG-517 after nerve injury promotes peripheral axonal regeneration in rats. *Mol. Pain* **14**, 1-10 (2018).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM